Please assess the completion status of the following clinical trial:

Trial Title: A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed clinical diagnosis of ulcerative colitis (UC) at least 3 months before screening~* Moderately to severely active UC as defined by Mayo score~* History of inadequate response to or failure to tolerate conventional therapy~* Has screening laboratory test results within the study protocol defined parameters~* A woman of childbearing potential must have a negative highly sensitive serum (beta human chorionic gonadotropin) pregnancy test result at screening and a negative urine pregnancy test result at Week 0~Exclusion Criteria:~* Has severe extensive colitis as defined in the study protocol~* Has UC limited to the rectum only or to less than (\<) 20 centimeter (cm) of the colon~* Has a history of latent or active granulomatous infection, including histoplasmosis or coccidioidomycosis, before screening~* Has any known malignancy or has a history of malignancy (with the exception of basal cell carcinoma; squamous cell carcinoma in situ of the skin; or cervical carcinoma in situ that has been treated with no evidence of recurrence; or squamous cell carcinoma of the skin that has been treated with no evidence of recurrence within 5 years before screening)~* Has known allergies, hypersensitivity, or intolerance to guselkumab or golimumab or their excipients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Combination Therapy (Type: EXPERIMENTAL): Participants will receive guselkumab Dose 1 as intravenous (IV) infusion and Dose 2 as subcutaneous (SC) injection; and golimumab Dose 1 and Dose 2 as SC injection and placebo to maintain the blind.
- Monotherapy: Guselkumab (Type: EXPERIMENTAL): Participants will receive guselkumab Dose 1 as IV infusion, Dose 2 as SC injection and placebo to maintain the blind.
- Monotherapy: Golimumab (Type: ACTIVE_COMPARATOR): Participants will receive golimumab Dose 1 and Dose 2 as SC injection and placebo to maintain the blind.

Based on this trial design, predict the completion outcome and termination type (if applicable).